Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pneumococcal 13-valent conjugate vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Single dose of NeisVac-C vaccine at 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age |
| Group 2 | EXPERIMENTAL | Single dose of NeisVac-C vaccine at 6 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age |
| Group 3 | ACTIVE_COMPARATOR | Two doses of NeisVac-C vaccine at 2 and 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age |
| Name | Type | Description |
|---|---|---|
| Meningococcal group C polysaccharide conjugate vaccine | BIOLOGICAL | 0.5 mL dose, subcutaneous administration in right anterolateral thigh |
| Pneumococcal 13-valent conjugate vaccine | BIOLOGICAL | 0.5 mL dose, subcutaneous administration in right anterolateral thigh |
| Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine | BIOLOGICAL | 0.5 mL dose, subcutaneous administration in right anterolateral thigh |
Inclusion Criteria: * Subject is an infant aged 8 to 11 weeks at the time of first vaccination * Subject is clinically healthy as determined by the investigator's clinical judgment through collection of medical history and physical examination * Subject was born at full term of pregnancy (\>= 37 we...
Pneumococcal 13-valent conjugate vaccine is being studied for use in Neisseria Meningitidis, a bacterial infection. It is an investigational vaccine in Phase 3 clinical development, evaluated in a completed trial involving infants. The vaccine is being developed by Pfizer, Inc. (PFE).
Pneumococcal 13-valent conjugate vaccine is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE. The vaccine is currently in Phase 3 clinical development for Neisseria Meningitidis infection.
Pneumococcal 13-valent conjugate vaccine is in Phase 3 clinical development. It is an investigational vaccine for Neisseria Meningitidis, and it has completed one Phase 3 trial. The vaccine is not yet approved and remains under clinical investigation.
Pneumococcal 13-valent conjugate vaccine has one completed Phase 3 clinical trial, identified as NCT01218451, titled "NeisVac-C Single Prime Study in Infants." The trial enrolled 956 participants, including infants aged 8 weeks and older, and was conducted in Poland and Spain.
Pneumococcal 13-valent conjugate vaccine is associated with the trial titled "NeisVac-C Single Prime Study in Infants," which evaluates the vaccine in infants. The trial name references NeisVac-C, but the vaccine itself is identified as Pneumococcal 13-valent conjugate vaccine in the clinical development program.